PURPOSE: Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity. MATERIALS AND METHODS: Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle. RESULTS: Of the 86 participants (mean age, 48.5 years; range 20 approximately 65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once. CONCLUSIONS: The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.
PURPOSE:Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity. MATERIALS AND METHODS: Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle. RESULTS: Of the 86 participants (mean age, 48.5 years; range 20 approximately 65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once. CONCLUSIONS: The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.
Authors: D Cardinale; M T Sandri; A Martinoni; A Tricca; M Civelli; G Lamantia; S Cinieri; G Martinelli; C M Cipolla; C Fiorentini Journal: J Am Coll Cardiol Date: 2000-08 Impact factor: 24.094
Authors: K Nysom; K Holm; S R Lipsitz; S M Mone; S D Colan; E J Orav; S E Sallan; J H Olsen; H Hertz; J R Jacobsen; S E Lipshultz Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544
Authors: Michael S Ewer; Mary T Vooletich; Jean-Bernard Durand; Myrshia L Woods; Joseph R Davis; Vicente Valero; Daniel J Lenihan Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: E H Herman; S E Lipshultz; N Rifai; J Zhang; T Papoian; Z X Yu; K Takeda; V J Ferrans Journal: Cancer Res Date: 1998-01-15 Impact factor: 12.701
Authors: D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia Journal: Ann Intern Med Date: 1979-11 Impact factor: 25.391
Authors: J L Speyer; M D Green; E Kramer; M Rey; J Sanger; C Ward; N Dubin; V Ferrans; P Stecy; A Zeleniuch-Jacquotte Journal: N Engl J Med Date: 1988-09-22 Impact factor: 91.245
Authors: S E Lipshultz; S R Lipsitz; S M Mone; A M Goorin; S E Sallan; S P Sanders; E J Orav; R D Gelber; S D Colan Journal: N Engl J Med Date: 1995-06-29 Impact factor: 91.245
Authors: Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Alessandro Colombo; Maria T Sandri; Michela Salvatici; Carlo M Cipolla; Daniela Cardinale Journal: Curr Treat Options Cardiovasc Med Date: 2014-06